Welcome!

News Feed Item

Envisia Therapeutics Announces Appointments to Board of Directors

Envisia Therapeutics today announced that it has made two appointments to the company’s board of directors. Effective immediately, Adrienne Graves, Ph.D. and Gary Phillips, M.D. will join the board as non-executive members.

“We are extremely honored to have these two respected industry leaders join the Board of Directors of Envisia early in the lifecycle of our company, which we believe is paving the way for a potentially transformative line of innovative ocular therapeutics,” said Neal Fowler, Chief Executive Officer of Envisia Therapeutics. “Both appointments bring invaluable perspective and insights that are greatly complementary to that of our existing board, forming a team that will collectively help us position Envisia as a leader in developing cutting-edge solutions for the ophthalmology community.”

A global thought leader in ophthalmology, Dr. Adrienne Graves currently serves as an independent director on a number of corporate boards, including Akorn, Inc.; TearLab Corporation; Aerpio Therapeutics; and Encore Vision. She is also a director on a number of ophthalmology-related foundation boards, including the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation (GRF), American Academy of Ophthalmology (AAO) Foundation (Emeritus), Himalayan Cataract Project, and KeepYourSight Foundation. Dr. Graves also cofounded Glaucoma 360 (Glaucoma Research Foundation) and Ophthalmic Women Leaders (OWL). Additionally, she serves on the Corporation Committee for the Brown University Medical School and the Advisory Board for Amach Capital Partners.

“Much progress has been made in the field of ophthalmology; however, the rate of preventable vision loss and blindness continues to rise and underscores the near-term need for truly innovative ocular therapies,” said Adrienne Graves, Ph.D. “Envisia’s application of the PRINT® technology to address unmet needs in ophthalmology could have a profound impact on our ability to reduce the rate of preventable vision loss, and I look forward to working with the company on its efforts to achieve this worthy goal.”

Dr. Graves was formerly President and Chief Executive Officer of Santen USA, a division of Santen Co. Ltd., Japan’s largest ophthalmic pharmaceutical company. She started her successful career with Santen USA in 1995 as Vice President of Clinical Affairs with responsibility for initiating the company’s U.S. clinical program, which included the approval of three New Drug Applications. Prior to joining Santen, she spent nine years with Alcon Laboratories, Inc., beginning as a Senior Scientist and then advancing into various roles, including Director of International Ophthalmology. Dr. Graves received her AB in Psychology with honors from Brown University and her Ph.D. in Psychobiology from the University of Michigan, and she completed a postdoctoral fellowship in visual neuroscience at the University of Paris.

Dr. Gary Phillips has more than 20 years’ experience in strategy, business development and licensing, commercial operations, business analytics, and clinical medicine in the pharmaceutical and healthcare industries. He is currently the Senior Vice President and Chief Strategy Officer at Mallinckrodt Pharmaceuticals.

“The ophthalmology market is attractive and highly concentrated among a few competitors; therefore, new entrants must be clearly differentiated through improved technologies that deliver marked improvement in patient outcomes while reducing the cost burden on patients and the healthcare system,” said Gary Phillips, M.D. “Through its unique combination of talent, technology, and vision, Envisia is well positioned to compete in this market, and I look forward to working with the company’s board and management team toward the goal of maximizing its potential in the years to come.”

Before joining Mallinckrodt, Dr. Phillips served as Head of Global Health and Healthcare Industries at the World Economic Forum in Geneva, Switzerland. Previously, he was President of Reckitt Benckiser Pharmaceuticals, Inc., and held the dual roles of President, U.S. Surgical and Pharmaceuticals and Global Head of Pharmaceuticals at Bausch & Lomb Incorporated. He has also held executive roles at Merck Serono, Novartis, and Wyeth (now Pfizer) and served as a healthcare strategy management consultant at Towers Perrin (now Towers Watson) and as a medical officer with the United States Navy. Dr. Phillips attended the University of Pennsylvania, where he earned a medical degree from the School of Medicine, an MBA from the Wharton School, and a Bachelor’s degree summa cum laude in biochemistry from the College of Arts and Sciences. He completed his postgraduate medical education at Naval Medical Center San Diego.

ABOUT ENVISIA THERAPEUTICS™

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately-held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, implantable extended-release formulation of travoprost (a marketed prostaglandin analogue) that has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina. For more information, please visit www.envisiatherapeutics.com.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, discussed how they built...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...
Digital Transformation (DX) is not a "one-size-fits all" strategy. Each organization needs to develop its own unique, long-term DX plan. It must do so by realizing that we now live in a data-driven age, and that technologies such as Cloud Computing, Big Data, the IoT, Cognitive Computing, and Blockchain are only tools. In her general session at 21st Cloud Expo, Rebecca Wanta explained how the strategy must focus on DX and include a commitment from top management to create great IT jobs, monitor ...
"Digital transformation - what we knew about it in the past has been redefined. Automation is going to play such a huge role in that because the culture, the technology, and the business operations are being shifted now," stated Brian Boeggeman, VP of Alliances & Partnerships at Ayehu, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Digital transformation is about embracing digital technologies into a company's culture to better connect with its customers, automate processes, create better tools, enter new markets, etc. Such a transformation requires continuous orchestration across teams and an environment based on open collaboration and daily experiments. In his session at 21st Cloud Expo, Alex Casalboni, Technical (Cloud) Evangelist at Cloud Academy, explored and discussed the most urgent unsolved challenges to achieve f...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
There is a huge demand for responsive, real-time mobile and web experiences, but current architectural patterns do not easily accommodate applications that respond to events in real time. Common solutions using message queues or HTTP long-polling quickly lead to resiliency, scalability and development velocity challenges. In his session at 21st Cloud Expo, Ryland Degnan, a Senior Software Engineer on the Netflix Edge Platform team, will discuss how by leveraging a reactive stream-based protocol,...
"I focus on what we are calling CAST Highlight, which is our SaaS application portfolio analysis tool. It is an extremely lightweight tool that can integrate with pretty much any build process right now," explained Andrew Siegmund, Application Migration Specialist for CAST, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Evatronix will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Evatronix SA offers comprehensive solutions in the design and implementation of electronic systems, in CAD / CAM deployment, and also is a designer and manufacturer of advanced 3D scanners for professional applications.
SYS-CON Events announced today that Synametrics Technologies will exhibit at SYS-CON's 22nd International Cloud Expo®, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Synametrics Technologies is a privately held company based in Plainsboro, New Jersey that has been providing solutions for the developer community since 1997. Based on the success of its initial product offerings such as WinSQL, Xeams, SynaMan and Syncrify, Synametrics continues to create and hone inn...
As many know, the first generation of Cloud Management Platform (CMP) solutions were designed for managing virtual infrastructure (IaaS) and traditional applications. But that's no longer enough to satisfy evolving and complex business requirements. In his session at 21st Cloud Expo, Scott Davis, Embotics CTO, explored how next-generation CMPs ensure organizations can manage cloud-native and microservice-based application architectures, while also facilitating agile DevOps methodology. He expla...
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices to ...
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
DevOps promotes continuous improvement through a culture of collaboration. But in real terms, how do you: Integrate activities across diverse teams and services? Make objective decisions with system-wide visibility? Use feedback loops to enable learning and improvement? With technology insights and real-world examples, in his general session at @DevOpsSummit, at 21st Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, explored how leading organizations use data-driven DevOps to close th...
"WineSOFT is a software company making proxy server software, which is widely used in the telecommunication industry or the content delivery networks or e-commerce," explained Jonathan Ahn, COO of WineSOFT, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.